Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Significant coronary artery stenosis (\>70% by visual estimate)~* Elective coronary stent implantation~Exclusion Criteria:~* Acute myocardial infarction~* Active bleeding and bleeding diatheses~* Hemodynamic instability~* Oral anticoagulation therapy with warfarin~* Use of peri-procedural glycoprotein IIb/IIIa inhibitors~* Contraindication to antiplatelet therapy~* Left ventricular ejection fraction \< 30%~* Leukocyte count \< 3,000/mm3, platelet count \< 100,000/mm3, AST or ALT ≥ 3 times upper normal~* Serum creatinine level ≥ 3 mg/dL~* Stroke within 3 months~* Noncardiac disease with a life expectancy \< 1 year~* Inability to follow the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adjunctive cilostazol (Type: ACTIVE_COMPARATOR): adjunctive cilostazol 100mg bid to dual antiplatelet therapy
- high maintenance-dose clopidogrel (Type: ACTIVE_COMPARATOR): double dose of clopidogrel 150mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).